The Modern Data Company and Thoughtworks Form Strategic Alliance to Accelerate Data Mesh Implementations and AI Initiatives
18.7.2023 13:12:00 EEST | Business Wire | Press release
The Modern Data Company, pioneers of the world's first data operating system, DataOS®, is thrilled to announce a strategic partnership with renowned global technology consultancy, Thoughtworks (NASDAQ: TWKS). This groundbreaking collaboration is set to reimagine data operations and accelerate the adoption of Data Products, Data Mesh, and AI initiatives across a wide range of industries.
Harnessing its rich expertise in data strategies, Thoughtworks has led numerous successful data transformation initiatives. The pairing of this experience with the technologically advanced Modern Data Company’s DataOS Platform--designed to streamline creation and management of Data Products, the key ingredients for a Data Mesh implementation--forms the backbone of this partnership. This collaborative alliance is set to unlock the full potential of organizational data, spearhead innovation, and pave the way for successful data modernization initiatives.
“The partnership between Modern and Thoughtworks marks a significant step as we transform how data is implemented and applied across an organization. We're changing the game by moving from traditional tables to a Data Product approach, and this collaboration significantly advances our shared vision. At The Modern Data Company, we firmly believe that the future lies in viewing and treating data as a product. This reimagining enables rapid, comprehensive creation and management of data, accelerating innovation and unlocking its full potential,” said Srujan Akula, CEO, The Modern Data Company. “By pairing Thoughtworks' profound expertise in data strategies with our innovative DataOS platform, we're poised to bring about a transformative shift in how organizations leverage their data.”
DataOS is an integrated platform that simplifies and expedites data development cycles. It equips teams with the comprehensive tools to easily build, manage, deploy, and iterate on their data products, all while ensuring seamless compatibility with the existing data infrastructure. This enables businesses to use their data assets without interruptions, maximizing derived value.
“The Modern Data Company and Thoughtworks have partnered to combine the world’s first data operating system, Modern’s DataOS, and Thoughtworks’ world-class data engineering and AI practices to help you thrive in today’s data-driven economy,” said John Spens, VP Data & AI Service Line, Thoughtworks. “Accelerate insights to drive your business by delivering transparent, trustworthy and accessible data efficiently and well.”
Stay tuned for more updates on this strategic partnership. For more information about The Modern Data Company and Thoughtworks, please visit their websites at https://TheModernDataCompany.com and https://Thoughtworks.com, respectively.
About The Modern Data Company:
The Modern Data Company offers comprehensive data management products. Our flagship product, DataOS®, is a data operating system pioneered to build comprehensive data products and accelerate the adoption of data mesh implementations so that organizations become truly data-driven and AI-ready.
See The Modern Data Company at CDOIQ 2023 in Cambridge, MA. at Booth #29 to learn more about data products and data mesh implementations.
About Thoughtworks
Thoughtworks is a global technology consultancy with more than 12,500 employees in 50 offices across 18 countries. It integrates strategy, design, and software engineering services for clients ranging from global Fortune 500 enterprises to digital natives and digital scaleups in industries like automotive, retail, financial services, healthcare, and the public sector. Founded in 1993, Thoughtworks is headquartered in Chicago.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718888038/en/
Contact information
Press Contact:
Emanuel Younanzadeh
VP Marketing
The Modern Data Company
emanuel@tmdc.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom